Imaging Diagnosis of Right Ventricle Involvement in Chagas Cardiomyopathy

Romano, Minna Moreira Dias; Moreira, Henrique T.; Schmidt, André; Maciel, Benedito Carlos; Marin-Neto, José Antônio

doi:10.1155/2017/3820191

Cited by 15 publications

(24 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In Chagas disease patients, dysfunction and dilation only of the LV have historically been studied; however, recent studies have demonstrated that RV dysfunction and dilation are predominantly seen in Chagas disease patients with heart failure [1,17]. Enlargement of the liver and other signs of systemic and pulmonary congestion are also commonly observed in severe CCM patients who die after the onset of heart failure [18].…”

Section: Introductionmentioning

confidence: 99%

Diet Alters Serum Metabolomic Profiling in the Mouse Model of Chronic Chagas Cardiomyopathy

Lizardo¹,

Ayyappan²,

Ganapathi³

et al. 2019

Disease Markers

View full text Add to dashboard Cite

Chagas disease is caused by Trypanosoma cruzi which is endemic in Latin America. T. cruzi infection results in a latent infection with approximately a third of latently infected patients developing chronic Chagas cardiomyopathy (CCM). CCM is a common cause of cardiomyopathy in endemic regions and has a poor prognosis compared to other cardiomyopathies. The factors responsible for the transition from the asymptomatic indeterminate latent stage of infection to CCM are poorly understood. Our previous studies demonstrated that lipid metabolism and diet are important determinants of disease progression. In the present study, we analyzed various serum metabolomic biomarkers such as acylcarnitines, amino acids, biogenic amines, glycerophospholipids, and sphingolipids in murine models of CCM, where the mice specifically develop either left or right ventricular cardiomyopathy based on the diets fed during the indeterminate stage in a murine model of Chagas disease. Our data provide new insights into the metabolic changes that may predispose patients to CCM and biomarkers that may help predict the risk of developing cardiomyopathy from T. cruzi infection. Author Summary. Chronic Chagas cardiomyopathy (CCM) is a parasitic disease prevalent in Latin America. Currently, no effective drugs or vaccines are available to prevent or cure CCM. The factors involved in the disease severity and progression are poorly understood to design new therapeutic interventions. In order to rapidly identify Chagas patients with a higher risk to develop CCM, a new set of biomarkers specific to Chagas disease is needed. We performed serum metabolomic analyses in chronic T. cruzi-infected mice fed on different diets and identified cardiac ventricular-specific metabolite biomarkers that could define CCM severity. In this paper, we present the results of serum metabolomic analyses and discuss its correlations to the diet-induced metabolic regulations in the pathogenesis of CCM in a murine model of Chagas disease.

show abstract

Section: Introductionmentioning

confidence: 99%

Diet Alters Serum Metabolomic Profiling in the Mouse Model of Chronic Chagas Cardiomyopathy

Lizardo¹,

Ayyappan²,

Ganapathi³

et al. 2019

Disease Markers

View full text Add to dashboard Cite

show abstract

“…A disfunção diastólica pode ser considerada como um marcador precoce da doença, em populações de áreas não endêmicas e que os sinais de cardiomiopatia dilatada foram mais frequentes em pacientes com múltiplas anormalidades eletrocardiográficas. (PEREIRA JUNIOR et al, 2014;FERNANDEZ et al, 2015;SÁNCHEZ-MONTALVÁ et al, 2016;ROMANO et al, 2017).…”

Section: Apresentação E Discussão Dos Resultadosunclassified

“…Na forma com comprometimento leve a moderado do VE evidenciou uma redução global da função sistólica de todos os parâmetros. Além disso, pacientes com a forma indeterminada tiveram velocidades longitudinais mais baixas e os seguimentos inferiores foram os mais afetados, o que pode indicar o início de uma lesão miocárdica (BARBOSA et al, 2014;PEREIRA JUNIOR et al, 2014;LIMA et al, 2016;ROMANO et al, 2017;NUNES et al, 2018).…”

Section: Apresentação E Discussão Dos Resultadosunclassified

Atualização no diagnóstico por imagem da miocardiopatia chagásica: uma revisão bibliográfica

Mendes

Guimarães

Hott

et al. 2020

BJD

View full text Add to dashboard Cite

show abstract

“…Conversely, an overall effect in favor of T. cruzi infection was identified for β -adrenergic density. There is no doubt that the heart is highly parasitized and damaged by T. cruzi [ 75 , 76 ]. Structural and electromechanical cardiac damage is the most serious manifestation of Chagas disease and is closely associated with morbidity and mortality, especially in the chronic phase of infection [ 77 – 79 ].…”

Section: Discussionmentioning

confidence: 99%

Relevance of Trypanothione Reductase Inhibitors on Trypanosoma cruzi Infection: A Systematic Review, Meta‐Analysis, and In Silico Integrated Approach

Mendonça

Coelho

Veloso

et al. 2018

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Due to the rudimentary antioxidant defenses in Trypanosoma cruzi, disruptors of redox balance are promising candidates for new antitrypanosomal drugs. We developed an integrated model based on systematic review, meta-analyses, and molecular modeling to evaluate the effect of trypanothione reductase (TR) inhibitors in T. cruzi infections. Our findings indicated that the TR inhibitors analyzed were effective in reducing parasitemia and mortality due to Trypanosoma cruzi infection in animal models. The most investigated drugs (clomipramine and thioridazine) showed no beneficial effects on the occurrence of infection-related electrocardiographic abnormalities or the affinity and density of cardiac β-adrenergic receptors. The affinity between the tested ligands and the active site of TR was confirmed by molecular docking. However, the molecular affinity score was unable to explain TR inhibition and T. cruzi death in vitro or the antiparasitic potential of these drugs when tested in preclinical models of T. cruzi infection. The divergence of in silico, in vitro, and in vivo findings indicated that the anti-T. cruzi effects of the analyzed drugs were not restricted to TR inhibition. As in vivo studies on TR inhibitors are still scarce and exhibit methodological limitations, mechanistic and highly controlled studies are required to improve the quality of evidence.

show abstract

Imaging Diagnosis of Right Ventricle Involvement in Chagas Cardiomyopathy

Cited by 15 publications

References 80 publications

Diet Alters Serum Metabolomic Profiling in the Mouse Model of Chronic Chagas Cardiomyopathy

Diet Alters Serum Metabolomic Profiling in the Mouse Model of Chronic Chagas Cardiomyopathy

Atualização no diagnóstico por imagem da miocardiopatia chagásica: uma revisão bibliográfica

Relevance of Trypanothione Reductase Inhibitors on Trypanosoma cruzi Infection: A Systematic Review, Meta‐Analysis, and In Silico Integrated Approach

Contact Info

Product

Resources

About